Medical Doctor Program year 2023 Reported 2019–2023 Source: CMS Open Payments, 2026 publication

Christopher Manning

Rheumatology Southington, CT Medical Doctor

NPI 1437124963 CMS profile 200695

1131 West St, Bldg 1 Ste 1, Southington, CT 06489

Open in the dashboard

General payments

$8,663

366 records reported · program years 2019–2023

Research payments

$0

Paid to them · None reported · program years 2019–2023

Ownership & investment interest

$0

None reported

Through program year 2023, Christopher Manning of Southington, CT is reported in the CMS Open Payments database as having received $8,663 across 366 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 69th percentile of Rheumatology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2023 General $101 5
2022 General $1,996 121
2021 General $1,256 86
2020 General $1,093 67
2019 General $4,217 87

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Christopher Manning
  • Rheumatology median
  • Middle half of Rheumatology
  • National median

In program year 2025, general payments to Christopher Manning were reported at $0. Among 4,454 Rheumatology profiles paid that year, the median was $903 and the middle half received between $171 and $2,775.

Show as a table
Year Christopher Manning Rheumatology median Middle half National median
2019 $4,217 $744 $153–$2,687 $163
2020 $1,093 $462 $98–$2,027 $114
2021 $1,256 $531 $101–$2,153 $132
2022 $1,996 $627 $125–$2,303 $149
2023 $101 $741 $145–$2,524 $160
2024 $0 $830 $166–$2,660 $164
2025 $0 $903 $171–$2,775 $169

Breakdown

Who paid General payments · program years 2019–2023
  1. Horizon Therapeutics plc $3,341 41 payments
  2. Janssen Biotech, Inc. $564 55 payments
  3. Amgen Inc. $544 36 payments
  4. Mallinckrodt Hospital Products Inc. $495 35 payments
  5. AbbVie, Inc. $402 32 payments
  6. Lilly USA, LLC $360 21 payments
  7. Pfizer Inc. $349 20 payments
  8. AstraZeneca Pharmaceuticals LP $330 15 payments
  9. GlaxoSmithKline, LLC. $319 17 payments
  10. Genentech, Inc. $240 5 payments
  11. Other $1,720 89 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2023
  1. Food and Beverage $5,760 356 payments
  2. Honoraria $2,250 1 payment
  3. Education $496 8 payments
  4. Travel and Lodging $157 1 payment
Products named General payments · program years 2019–2023
  1. KRYSTEXXA $3,225 32 payments
  2. ACTHAR $495 35 payments
  3. SIMPONI ARIA $409 46 payments
  4. STELARA $409 46 payments
  5. TALTZ $360 21 payments
  6. SAPHNELO $330 15 payments
  7. Rituxan $324 13 payments
  8. BENLYSTA $319 17 payments
  9. RINVOQ $308 26 payments
  10. Prolia $307 18 payments
  11. Other $3,978 242 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

366 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2023

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record